M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous Nephropathy

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies.

current concepts on anti-phospholipase a2 receptor antibody in idiopathic membranous nephropathy.

letter to the editor

Chapter 7: Idiopathic membranous nephropathy

BACKGROUND The diagnosis of MN is made on kidney biopsy. Diagnostic features include capillary wall thickening, normal cellularity, IgG and C3 along capillary walls on immunofluorescence, and subepithelial deposits on electron microscopy. MN is often seen in association with an underlying disorder (secondary MN). Secondary MN is more common in children (75%) than adults (25%) (Table 12). The di...

Treatment of idiopathic membranous nephropathy.

Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Ri...

Treatment with rituximab in idiopathic membranous nephropathy

BACKGROUND Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic protocols is not yet defined. METHODS We studied 38 patients with idiopathic MN treated with rituximab (in 13 patients as first-line t...